News

30th May 2018

Preclinical Alzheimer’s unlikely to lead to dementia, new study reports

https://www.brainwork.md/content/uploads/2018/05/Brainwork-Alzheimers.jpg 1200 829 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 30th May 2018 13th July 2018

New data from a multi-study analysis has unveiled that preclinical Alzheimer’s disease (AD) will not lead to severe dementia in the majority of cases. The paper marks the first time…

Peter Stevenson, PhD
0
0

27th May 2018

FDA approves blockbuster migraine treatment

https://www.brainwork.md/content/uploads/2018/05/Brainwork-FDAApproves.jpg 1200 800 Mea Holm, PhD Mea Holm, PhD https://secure.gravatar.com/avatar/7a927c1dcef51229f6403ce27328c69e?s=96&d=mm&r=g 27th May 2018 13th July 2018

On May 17th, 2018, the US FDA approved Aimovig™ (erenumab) following successful phase III trials. Aimovig™, co-developed by Amgen and Novartis, is the first approved migraine treatment targeting the calcitonin gene…

Mea Holm, PhD
1
0

25th May 2018

Machine learning offers automated diagnosis in stroke and dementia

https://www.brainwork.md/content/uploads/2018/05/Brainwork-MachineLearning-v2.jpg 1200 800 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 25th May 2018 13th July 2018

Researchers have harnessed the power of artificial intelligence (AI) to identify a key cause of dementia and stroke – and with stunning accuracy – a new study reports. Created by…

Peter Stevenson, PhD
0
0

23rd May 2018

“Ask the audience”: Stroke debates feature at ESOC 2018

https://www.brainwork.md/content/uploads/2018/05/Brainwork-StrokeContraversies.jpg 1600 2400 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 23rd May 2018 13th July 2018

Controversies in stroke were laid bare at the recent European Stroke Organisation Conference (ESOC) in Gothenburg, Sweden, in a special session that saw experts rallying to convince the audience of…

Peter Stevenson, PhD
0
0

18th May 2018

First MS treatment approved for children & adolescents

https://www.brainwork.md/content/uploads/2018/05/Brainwork-MSAdolescents.jpg 1600 1067 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 18th May 2018 13th July 2018

The US Food and Drug Administration (FDA) has approved the use of fingolimod (Gilenya®, Novartis, Basel, Switzerland) for the treatment of paediatric patients aged 10 to 18 years with relapsing…

Peter Stevenson, PhD
0
0

15th May 2018

Saunas linked to reduced stroke risk

https://www.brainwork.md/content/uploads/2018/05/Brainwork-StrokeRisk.jpg 1200 800 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 15th May 2018 13th July 2018

Regular use of saunas could be key in reducing stroke risk, a new European study reports. Baseline sauna habits of 1,628 men and women (age 53–74 years; mean 62.7) without prior…

Peter Stevenson, PhD
0
0

9th May 2018

Start MS drugs early, say new guidelines

https://www.brainwork.md/content/uploads/2018/05/Brainwork-MSGuidelines.jpg 1400 885 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 9th May 2018 13th July 2018

Drug therapy for multiple sclerosis (MS) should be started early, according to updated guidelines from the American Academy of Neurology (AAN), which were presented at the recent AAN annual meeting…

Peter Stevenson, PhD
0
1

30th April 2018

Solriamfetol improves wakefulness in narcolepsy patients

https://www.brainwork.md/content/uploads/2018/04/Brainwork-Solriamfetol.jpg 1920 1280 Lutz Achtnichts, MD Lutz Achtnichts, MD https://secure.gravatar.com/avatar/c84206ad1869ec28d770e94fa456ef6d?s=96&d=mm&r=g 30th April 2018 13th July 2018

This year’s American Academy of Neurology (AAN) meeting featured results of a randomised, placebo-controlled phase III study evaluating the safety and efficacy of solriamfetol for the treatment of excessive sleepiness (ES) in…

Lutz Achtnichts, MD
0
1

30th April 2018

Huntington’s disease: Antisense drug showing promising results

https://www.brainwork.md/content/uploads/2018/04/Brainwork-HuntingtonsDisease.jpg 4288 3216 Lutz Achtnichts, MD Lutz Achtnichts, MD https://secure.gravatar.com/avatar/c84206ad1869ec28d770e94fa456ef6d?s=96&d=mm&r=g 30th April 2018 13th July 2018

Results from a Phase I/IIa study of IONIS-HTTRx (RG6042) in Huntington’s disease (HD) were presented in a plenary session at the 2018 annual meeting of the American Academy of Neurology (AAN). Results…

Lutz Achtnichts, MD
0
1

26th April 2018

Promising new migraine treatment presented at AAN 2018

https://www.brainwork.md/content/uploads/2018/04/Brainwork-Erenumab.jpg 5184 3456 Lutz Achtnichts, MD Lutz Achtnichts, MD https://secure.gravatar.com/avatar/c84206ad1869ec28d770e94fa456ef6d?s=96&d=mm&r=g 26th April 2018 13th July 2018

Migraine is consistently ranked among the top 20 most burdensome diseases worldwide. Until now, existing prophylactic therapies for episodic migraine consisted mostly of repurposed medications for other conditions. They are…

Lutz Achtnichts, MD
0
2

Preclinical Alzheimer’s unlikely to lead to dementia, new study reports

FDA approves blockbuster migraine treatment

Machine learning offers automated diagnosis in stroke and dementia

“Ask the audience”: Stroke debates feature at ESOC 2018

First MS treatment approved for children & adolescents

​Saunas linked to reduced stroke risk

Start MS drugs early, say new guidelines​

Solriamfetol improves wakefulness in narcolepsy patients

​Huntington’s disease: Antisense drug showing promising results

​Promising new migraine treatment presented at AAN 2018

Saunas linked to reduced stroke risk

Start MS drugs early, say new guidelines

Huntington’s disease: Antisense drug showing promising results

Promising new migraine treatment presented at AAN 2018